Description
Developer of drugs and therapies in field of oncology. The company develops, researches and commercializes new drugs and technologies in the field of oncology and medicine.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Grant | 22-Jan-2014 | $292K | 000.00 | Completed | Startup | |
1. Angel (individual) | 22-Jan-2014 | 000.00 | 000.00 | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9957236-B2 | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases | Active | 22-May-2014 | 0000000000 | 00 |
ES-2734649-T3 | Selective inhibitors that interfere with the interaction of the fibroblast growth factor receptor and frs2 for the prevention and treatment of cancer and other diseases | Active | 22-May-2014 | 0000000000 | |
JP-2017530111-A | Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer | Granted | 22-May-2014 | 0000000000 | |
US-20170183315-A1 | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer and other diseases | Granted | 22-May-2014 | 0000000000 | 0 |
JP-6365999-B2 | Selective inhibitors that interfere with the interaction of frs2 with fibroblast growth factor receptor for the prevention and treatment of cancer | Active | 22-May-2014 | C07D239/42 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Tamara Timofeeva | Chief Executive Officer | ||
Sergey Tulyandin | Chief Scientific Officer |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Skolkovo Foundation | Limited Partner | 000 0000 | 000000 0 |